Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA

British Journal of Haematology

Volumn 103, Issue 3, 1998, Pages 610-617

  Vannucchi, Alessanndro M ^a,b   Bosi, Alberto ^a   Glinz, Stephanie ^a   Pacini, Paolo ^a   Linari, Silvia ^a   Saccardi, Riccardo ^a   Alterini, Renato ^a   Rigacci, Luigi ^a   Guidi, Stefano ^a   Lombardini, Letizia ^a   Longo, Giovanni ^a   Mariani, Maria P ^a   Rossi Ferrini, Pierluigi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Autologous transplantation; Breast cancer; Cytokeratin 19; Immunohistochemistry; Metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKERATIN 19; EPIRUBICIN; FLUOROURACIL; MESSENGER RNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BONE MARROW METASTASIS; BREAST CANCER; CANCER SURVIVAL; CELL SELECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTAMINATION; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKAPHERESIS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ADULT; ANTIGENS, CD34; BONE MARROW NEOPLASMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LEUKAPHERESIS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 7844252268     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.01027.x     Document Type: Article

References (44)

1. Bezwoda, W.R., Seymour. L. & Dansey, R.D. (1995) High-dose chemotherapy with hematopoielic rescue in melastatic breast canter: a randomized trial. Journal of Clinical Oncology, 13, 2483-2489.
2. Blomqyist, C., Elomaa, I., Rissanen, P., Hietanen, P., Nevasaari, K. & Helle, L. (1993) Influence of treatment schedule on toxicity and eflicacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. Journal of Clinical Oncology, 11, 467-473.
3. Brenner, M.K., Rill, D.R., Moen, R.C., Krance, R.A., Mirro. J., French, A.W, & Ihle, J.N. (1993) Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet, 341, 85-86.
4. Brugger, W., Bross, K.J., Glatt, M., Weber, F., Mertelsmann, R. & Kanz,. L. (1994) Mobilization of tumor tells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood, 85, 636-640.
5. Burchill, S.A., Bradbury, M.F., Pittman, K., Southgate, J., Smith, B. & Selby, P. (1995) Detection of epithelial cancer cells in peripheral blood by RT-PCR. British Journal of Cancer, 71, 278-281.
6. Cote, R.J., Rosen, P.P., Lesser, M.L., Old, L.J. & Osborne, P. (1991) Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastasis. Journal of Clinical Oncology. 9, 1749-1756.
7. Datta, Y.H., Adams, P.T., Drobyski, W, Ethier, S.P., Terry, V.H. & Roth, M.S. (1994) Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. Journal of Clinical Oncology, 12, 475-482.
8. 1 cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood, 83, 3068-3076.
9. Diel, I.J., Kaufmann, M., Goerner, R., Costa, S.D. & Basert, G, (1992) Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognosis factor for distant metastasis, Journal of Clinical Oncology. 10, 1534-1539.
10. Eddy. D.M. (1992) High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. Journal of Clinical Oncology 10, 657-670.
11. Fields. K.K., Elfenbein, G.J., Lazaraus, H.M., Cooper, B.W. Perkins, J.B., Creger. R.J., Ballester, O.F. Hiemenz. J.H., Jansen, W.E. & Zorsky, P.E. (1995) Maximum tolerated doses of ifosfamide, carboplatin and etoposide given over 6 days followed by autologous stem cell rescue: toxicity protile. Journal of Clinical Oncology. 13, 323-332.
12. Fields, K.K., Elfenbein, G.J., Trudeau, W.I,., Perkins, J.B., Janssen, W.E. & Moscinski, L.C. (1996) Clinical significance of bone marrow métastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. Journal of Clinical Oncology, 17. 1868-1876.
13. Gradishar, W.J., Tallman, M.S. & Abrains, J.S. (1996) High-dose chemotherapy for breast cancer. Annals of Internal Medicine, 125, 599-604.
14. Gribben, J.G., Freedman, A.S., Neuberg, D., Roy, D.J., Blake, K.W., Woo, S.D., Grossbard, M.L., Rabinowe, S.N., Coral. F., Freeman, G.J., Ritz. J. & Nadler, L.M. (1991) Immunologic purging of marrow assessed by PCR before autologous bone marrow trasplantation for B-cell lymphoma. New Gngland Journal of Medicine, 325, 1525-1533.
15. 7 .Proceedings of the National Academy of Sciences of the United States of America, 92, 537-541.
16. Harbeck, N., Untch, M., Pache, L. & Eiermann, W. (1994) Tumor cell deection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. International Journal of Cancer, 69, 566-571.
17. Hildebrandt, M., Mapara, M.Y., Koerner, I.J., Bargou, R. C., Moldenhauer. G. & Doerken, B. (1997) Reverse transcriptasepolymerase chain reaction (RT-PCR)-controlled immunomugnetic purging of breast cancer cells using the magnetic cell separation (MACS) system: a sensitive method for monitoring purging efficiency. Experimental Hematology 25, 57-65.
18. Hurd, D.D. & Peters. W.P. (1995) Randomized, comparative study of high-dose (with autologous hone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II or III breast cancer involving 10 or more axillary lymph nodes (CALGB Protocol 9082). Cancer and Leukemia Group B. Journal of the National Cancer Institute Monograph, 19, 41-44.
19. Krismann, M., Todt, B., Schroder, J., Gareis, D., Mueller, K-M., Seeber, S. & Schuette, J. (1995) Low specificity of cylokeralin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination, Journal of Clinical Oncology, 13, 2769-2775.
20. Kumar, V., Green, S., Stack, G., Berry, M., Jin, J.R. & Chambon, P. (1987) functional domains of the human estrogen receptor. Cell, 51, 941-951.
21. Long, G.D., Negrin, R.S., Hoyle, F., Kusnierz-Glaz. C.R., Schriber, J.R., Blume, K.G. & Nelson J.C. (1995) Multiple cycles of high-dose chemotherapy supported by hematopoietic progenitor cells as treatment of patients with advanced malignancies. Cancer, 76, 860-868.
22. Mansi, J.L., Easton, D., Berger, U., Gazet. J-C., Ford, H.T., Dearnaly, D. & Coombes, R.C. (1991) Hone marrow micrometastases in primary breast cancer: prognostic significance after 6 years follow-up. European Journal of Cancer, 27, 1552-1555.
23. Mapara, M.Y., Korner, I.J., Hildebrandt, M., Bargou, R., Reichart, P. & Doerken, B, (1997) Monitoring of tumor cell purging after highly efficient immuuomagnetic selection of CD 34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptasepolymerase chain reaction. Blood, 89, 337-344.
24. Moll, R., Frauke, W., Schiller, D.L., Geiger, B. & Krepler, R. (1982) The catalog of human cytokeratins: patterns of expression in normal epithelial tumors and cultured cells. Cell, 31, 11-24.
25. Passos-Coelho, J.L., Ross, A.A., Kahn, D.J., Moss, T.J., Davis, J.M., Huelskamp, A-M., Noga, S.J., Davidson, N.K. & Kennedy, M.J. (1996) Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. Journal of Clinical Oncology, 14, 2569-2575.
26. Pedrazzoli, R, Battaglia, M, Da Prada, G.A., Lanza, A., Cuomo, A., Bertolini, F., Pavesi, L. & Robustelli della Cuna. G. (1997) Role of tumor cells contaminating the graft in breast cancer recurrence aller high-dose chemotherapy. Bone Marrow Transplantation, 20, 157-169.
27. Peters, W.P., Ross, M., Vrendenburgh, J.J., Meisenberg, B., Marks, L.B., Winer, E., Kurtzberg, J., Bast, R.C., Jr, Jones, R. & Shpall, E. (1993a) High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Journal of Clinical Oncology, 11, 1132-1143.
28. Peters, W.P., Ross, M., Vredenburgh, J., Meisenberg, B., Marks, L.B., Winer, E., Kurtzberg, J., Bast, K.J., Jones, R., Shpall, K., Wu, K., Rosner, G., Gilbert, C., Mathias, B., Coniglio, D., Petros, W., Henderson, I.G., Norton, L., Weiss, R.B., Budman, D. & Hurd, D, (1993b) High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Journal of Clinical Oncology, 11, 1132-1145.
29. Rill, D.R., Santana, V.M., Roberts, W.M., Nilson, T., Bowman, L.C., Krance, R.A., Helshop, H.E., Moen, R.C., IhIe, J.N. & Brenner, M.K. (1994) Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 84, 380-383.
30. Ross, A.A., Cooper, B.W., Lazarus, H.M., Mackay, W., Moss, T.J., Ciobanu, N., Tallman, M.S., Kennedy, M.J., Davidson, N.E., Sweet, D., Winter, C., Akard, L., Jansen, J., Copelan, E., Meagher, R.C., Herzig, R.H., Klumpp, T.R., Kahn, D.C. & Warner, N.E. (1993) Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood, 82, 2605-2610.
31. Ross, A.A., Loudovaris, M., Hazelton, B., Weaver, C.H., Schwartzberg. L. & Bender, J.G. (1995) Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients. Experimental Hematology, 23, 1478-1483.
32. Ross, A.A., Layton, T.J., Ostrander, A.B., Passo-Coelho, J.L., Davis, J.M., Huelskamp, A.M., Noga, S.J., Davidson, N.E., Kennedy, M.J., Cooper, B.W., Gerson, S.L., Lazarus, H.M., Holland, K., Gluck, S., Moss, T.J., Kaubish, A., Vahdt, L. & Antman, K. (1996) Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts, Journal of Hematotherapy 5, 549-552.
33. Schlimok, G., Funke, I., Holzmann, B., Goettlinger, G., Schmidt, G., Haeuser, H., Swierkot, S., Warnecke, H.H., Schneider, B., Koprowski, H. & Riethmueller, G. (1987) Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeralin and in vivo labeling with anti-17-1A monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America, 84, 8672-8676.
34. Schulze, R., Schulze, M., Wischnik, A., Ehnle, S., Doukas, K., Behr, W., Ehret, W. & Schlimok, G. (1997) Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients. Bone Marrow Transplantation. 19, 1223-1228.
35. Shpall, E.J., LeMaistre, C.E., Holland, K., Ball, E., Jones, R.B., Saral, R., Jacobs, C., Heimfeld, S., Berenson, R. & Champlin, R. (1997) A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood, 90, 4313-4320.
36. Simpson, S.J., Vachula, M., Kennedy, M.J., Kaizer, H., Conn, J.S., Ghalie, R., Williams, S. & Van Epps, D. (1995) Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Experimental Hematology, 23, 1062-1068.
37. Traweek, S.T., Liu, J. & Battifora, H. (1993) Keratin gene expression in non-epithelial tissues: detection with polymerase chain reaction. American Journal of Pathology, 4, 1111-1117.
38. + peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells. Blood, 88, 2707-2713.
39. Vredenburgh, J.J., Silva, O., Tyer, C., DeSombre, K., Abou-Ghalia, A., Cook, M., Layfield, L., Peters, W.P. & Bast, R.C. (1996) A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the hone marrow. Journal of Hematotherapy. 5, 57-62.
40. Vredenburgh, J.J., Silva, O., Broadwater, G., Berry, D., DeSombre, K., Tyer, C., Petros, W.P., Peters, W.P. & Bast, R.C. (1997) The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biology of Blood and Bone Marrow Transplantation, 3, 91-97.
41. Watari, K., Mayani, H., Lee, F., Dragowska, W., Lansdorp, P.M. & Schrader, J.W. (1996) Production of interleukin 1β by human hematopoietic progenitor cells. Journal of Clinical Investigation, 97, 1666-1674.
42. Williams, S.F. (1995) Dose-intensive chemotherapy with autologous stem cell rescue in breast cancer. Advances in Oncology, 11, 11-18.
43. Wood, G.S., Warnke, R.A. (1982) The immunologic phenotyping of bone marrow biopsies and aspirates: frozen section techniques. Blood, 59, 913-917.
44. Ybanez, J., Lazarus, H.M., Ross, A.A. & Cooper, B. (1995) Impact of occult tumor reinfusion on outcome after high-dose chemotherapy in patients with advanced breast cancer. Blood, 86, 386 (Abstract 1532).